Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles

Babos, György; Biró, Emese; Meiczinger, Mónika; Feczkó, Tivadar

doi:10.3390/polym10080895

Cited by 70 publications

(41 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, we entrapped sorafenib and doxorubicin using PLGA and PEGylated PLGA nanocarriers [ 11 ], and experienced that the PEGylated PLGA showed faster drug release than PLGA, however, in that case, the PLGA was PEGylated by polymerization, and the ready PEGylated polymer was used for the dual drug microencapsulation. In contrast, with the PHB we applied PEG conjugation to the prepared sorafenib and doxorubicin co-loaded PHB nanoparticles.…”

Section: Resultsmentioning

confidence: 99%

“…They can also control the drug release and contain active targeting moieties besides passive enhanced permeability and retention effect. Currently, drug-loaded nanoparticles are usually prepared using polylactide [ 8 ], poly(lactic- co -glycolic acid) (PLGA) [ 9 ] and poly(-caprolactone) [ 10 ] or their copolymers especially with poly(ethylene glycol) (PEG) [ 11 , 12 ]. PEGylation of the particles is a promising method to increase the lifetime of the nanoparticles in the blood stream [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

“…Nanoparticles are commonly obtained by nanoprecipitation, emulsion techniques (single or double), or electrospraying methods [ 22 ]. Recently, we co-encapsulated sorafenib and doxorubicin using PLGA and PEGylated PLGAs [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery

Babos

Rydz

Kawalec

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Dual drug-loaded nanotherapeutics can play an important role against the drug resistance and side effects of the single drugs. Doxorubicin and sorafenib were efficiently co-encapsulated by tailor-made poly([R,S]-3-hydroxybutyrate) (PHB) using an emulsion–solvent evaporation method. Subsequent poly(ethylene glycol) (PEG) conjugation onto nanoparticles was applied to make the nanocarriers stealth and to improve their drug release characteristics. Monodisperse PHB–sorafenib–doxorubicin nanoparticles had an average size of 199.3 nm, which was increased to 250.5 nm after PEGylation. The nanoparticle yield and encapsulation efficiencies of drugs decreased slightly in consequence of PEG conjugation. The drug release of the doxorubicin was beneficial, since it was liberated faster in a tumor-specific acidic environment than in blood plasma. The PEG attachment decelerated the release of both the doxorubicin and the sorafenib, however, the release of the latter drug remained still significantly faster with increased initial burst compared to doxorubicin. Nevertheless, the PEG–PHB copolymer showed more beneficial drug release kinetics in vitro in comparison with our recently developed PEGylated poly(lactic-co-glycolic acid) nanoparticles loaded with the same drugs.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery

Babos

Rydz

Kawalec

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Poly(ethylene glycol)-b-poly(lactide-co-glycolide) (PEG-b-PGLA) seems to be a promising DDS [120][121][122], capable of passing the blood brain barrier [123,124]. Liu et al [125] investigated PEG 2000 / 5000 -b-PLGA (different ratio's) micelles on their biocompatibility and indicated that all micelles presented very low cytotoxicity.…”

Section: Peg-b-plgamentioning

confidence: 99%

Drug Delivery with Polymeric Nanocarriers—Cellular Uptake Mechanisms

Nelemans

Gurevich

2020

Materials

View full text Add to dashboard Cite

Nanocarrier-based systems hold a promise to become “Dr. Ehrlich’s Magic Bullet” capable of delivering drugs, proteins and genetic materials intact to a specific location in an organism down to subcellular level. The key question, however, how a nanocarrier is internalized by cells and how its intracellular trafficking and the fate in the cell can be controlled remains yet to be answered. In this review we survey drug delivery systems based on various polymeric nanocarriers, their uptake mechanisms, as well as the experimental techniques and common pathway inhibitors applied for internalization studies. While energy-dependent endocytosis is observed as the main uptake pathway, the integrity of a drug-loaded nanocarrier upon its internalization appears to be a seldomly addressed problem that can drastically affect the uptake kinetics and toxicity of the system in vitro and in vivo.

show abstract

“…The particle size (mean diameter), size distribution (polydispersity index, PDI) and zeta potential of the obtained nanoparticles were determined by a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) operated with dynamic light scattering. 35 Drug entrapment efficiency (EE) and loading capacity (LC) were analyzed using a UV spectrophotometer (Shimadzu, Kyoto, Japan) at 270 nm (for SFN) and 425 nm (for CCM). 36 The EE and LC were calculated by using equations:…”

Section: Characterization Of Nanoparticlesmentioning

confidence: 99%

<p>Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles</p>

Bian¹,

Guo²

2020

DDDT

View full text Add to dashboard Cite

Purpose: Hepatocellular carcinoma (HCC) is a leading cancer worldwide. In the present investigation, sorafenib (SFN) and curcumin (CCM) were co-delivered using pH-sensitive lactosylated nanoparticles (LAC-NPs) for targeted HCC treatment. Methods: pH-responsive lactosylated materials were synthesized. SFN and CCM codelivered, pH-responsive lactosylated nanoparticles (LAC-SFN/CCM-NPs) were selfassembled by using the nanoprecipitation technique. The nanoparticles were characterized in terms of particle size, charge and drug release profile. The anti-cancer effects of the nanoparticles were evaluated in human hepatic carcinoma cells (HepG2) cells and HCC tumor xenograft models. Results: LAC-SFN/CCM-NPs are spherical particles with light coats on the surface. The size and zeta potential of LAC-SFN/CCM-NPs were 115.5 ± 3.6 nm and −34.6 ± 2.4, respectively. The drug release of LAC-SFN/CCM-NPs in pH 5.5 was more efficient than in pH 7.4. LAC-SFN/CCM-NPs group exhibited the smallest tumor volume (239 ± 14 mm 3 ), and the inhibition rate of LAC-SFN/CCM-NPs was 77.4%. Conclusion: In summary, LAC-SFN/CCM-NPs was proved to be a promising system for targeted HCC therapy.

show abstract

Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles

Cited by 70 publications

References 18 publications

Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery

Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery

Drug Delivery with Polymeric Nanocarriers—Cellular Uptake Mechanisms

<p>Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles</p>

Contact Info

Product

Resources

About